GlassScriptPhysician profile
Bernadette Acevedo
NPI 1669733929
$4,985.55
in general payments reported to CMS, 2019-2025
20 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $1,513 · 2023: $926 · 2024: $932 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,336.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $738.10 | 2024-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $618.90 | 2022-2024 | Rinvoq, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $420.70 | 2024-2025 | |
| Genzyme Corporation | $414.03 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $375.86 | 2021-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $176.17 | 2023-2025 | Sotyktu, Eliquis |
| Galderma Laboratories, L.P. | $134.44 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $130.84 | 2022 | |
| Arcutis Biotherapeutics, INC. | $121.18 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.25 | 2025 | Jardiance |
| Sun Pharmaceutical Industries INC. | $90.34 | 2023 | Winlevi, Absorica Ld |
| Viiv Healthcare Company | $68.74 | 2022-2024 | Dovato |
| Merck Sharp & Dohme LLC | $50.38 | 2024 | Pifeltro, Delstrigo |
| Glaxosmithkline, LLC. | $47.70 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $47.15 | 2025 | Attruby |
| Genentech USA, INC. | $41.67 | 2021-2023 | Xolair |
| Daiichi Sankyo INC. | $29.44 | 2025 | Injectafer |
| Philips North America LLC | $21.51 | 2025 | Ecc Solutions |
| Ionis Pharmaceuticals, INC. | $17.55 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Acevedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.